{"id":13515,"date":"2024-11-19T14:28:39","date_gmt":"2024-11-19T06:28:39","guid":{"rendered":"https:\/\/flcube.com\/?p=13515"},"modified":"2024-11-19T14:28:42","modified_gmt":"2024-11-19T06:28:42","slug":"youjia-biomedical-and-yiling-pharmaceutical-collaborate-on-rnai-metabolic-disease-treatments","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=13515","title":{"rendered":"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments"},"content":{"rendered":"\n

China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered into a strategic cooperation agreement with Yiling Pharmaceutical Co., Ltd (SHE: 002603), marking a significant step into the metabolic diseases field utilizing RNAi technologies. This partnership aims to leverage Youjia’s expertise in nucleic acid drug development to create innovative treatments for metabolic disorders.<\/p>\n\n\n\n

Details of the Cooperation Agreement<\/strong>
Under the terms of the agreement, Yiling Pharmaceutical will secure the rights to future development, manufacturing, and commercialization of the resultant drug. Meanwhile, Youjia is set to receive upfront payments, milestone payments, and future sales commissions for their contributions both domestically and internationally.<\/p>\n\n\n\n

Youjia Bio’s Nucleic Acid Drug Development Platform<\/strong>
Founded in 2019, Youjia Bio boasts a state-of-the-art nucleic acid drug full-process development platform known as SEQUAD. This platform is designed to accelerate the development and industrialization of nucleic acid drugs and nucleic acid technology products. The collaboration with Yiling Pharmaceutical is expected to further enhance the capabilities of both companies in the field of metabolic disease treatments.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered…<\/p>\n","protected":false},"author":1,"featured_media":13517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[64,2072,2071,2190],"class_list":["post-13515","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-rnai-aso","tag-she-002603","tag-yiling-pharmaceutical","tag-youjia-biomedical-technology"],"yoast_head":"\nYoujia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered into a strategic cooperation agreement with Yiling Pharmaceutical Co., Ltd (SHE: 002603), marking a significant step into the metabolic diseases field utilizing RNAi technologies. This partnership aims to leverage Youjia's expertise in nucleic acid drug development to create innovative treatments for metabolic disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=13515\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=13515\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-19T06:28:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-19T06:28:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/640-10.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13515#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13515\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments\",\"datePublished\":\"2024-11-19T06:28:39+00:00\",\"dateModified\":\"2024-11-19T06:28:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13515\"},\"wordCount\":186,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13515#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/640-10.webp\",\"keywords\":[\"RNAi \\\/ ASO\",\"SHE: 002603\",\"Yiling Pharmaceutical\",\"Youjia Biomedical Technology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13515#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13515\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=13515\",\"name\":\"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13515#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13515#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/640-10.webp\",\"datePublished\":\"2024-11-19T06:28:39+00:00\",\"dateModified\":\"2024-11-19T06:28:42+00:00\",\"description\":\"China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered into a strategic cooperation agreement with Yiling Pharmaceutical Co., Ltd (SHE: 002603), marking a significant step into the metabolic diseases field utilizing RNAi technologies. This partnership aims to leverage Youjia's expertise in nucleic acid drug development to create innovative treatments for metabolic disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13515#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13515\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13515#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/640-10.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/640-10.webp\",\"width\":1080,\"height\":608,\"caption\":\"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13515#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments - Insight, China's Pharmaceutical Industry","description":"China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered into a strategic cooperation agreement with Yiling Pharmaceutical Co., Ltd (SHE: 002603), marking a significant step into the metabolic diseases field utilizing RNAi technologies. This partnership aims to leverage Youjia's expertise in nucleic acid drug development to create innovative treatments for metabolic disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=13515","og_locale":"en_US","og_type":"article","og_title":"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=13515","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-19T06:28:39+00:00","article_modified_time":"2024-11-19T06:28:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/640-10.webp","type":"image\/webp"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=13515#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=13515"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments","datePublished":"2024-11-19T06:28:39+00:00","dateModified":"2024-11-19T06:28:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=13515"},"wordCount":186,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=13515#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/640-10.webp","keywords":["RNAi \/ ASO","SHE: 002603","Yiling Pharmaceutical","Youjia Biomedical Technology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=13515#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=13515","url":"https:\/\/flcube.com\/?p=13515","name":"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=13515#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=13515#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/640-10.webp","datePublished":"2024-11-19T06:28:39+00:00","dateModified":"2024-11-19T06:28:42+00:00","description":"China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered into a strategic cooperation agreement with Yiling Pharmaceutical Co., Ltd (SHE: 002603), marking a significant step into the metabolic diseases field utilizing RNAi technologies. This partnership aims to leverage Youjia's expertise in nucleic acid drug development to create innovative treatments for metabolic disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=13515#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=13515"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=13515#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/640-10.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/640-10.webp","width":1080,"height":608,"caption":"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=13515#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/640-10.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13515"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13515\/revisions"}],"predecessor-version":[{"id":13518,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13515\/revisions\/13518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/13517"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}